Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market on Track for Strong Growth, Estimated to Grow at 8.5% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Through 2025?
The market size of the pharmaceutical contract development and manufacturing organization (CMO) has seen significant growth in recent years. From $174.33 billion in 2024, it is projected to increase to $184.39 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. The growth in the past years can be credited to robust economic development in burgeoning markets, escalated healthcare spending, burgeoning pharmaceutical research and development (R&D) expenditure, and a growing predilection for outsourcing.

What's the Projected Size of the Global Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market by 2029?
Anticipations of vigorous expansion are being made for the pharmaceutical contract development and manufacturing organization (CMO) market, projecting it will rise to "$255.58 billion in 2029," boasting a Compound Annual Growth Rate (CAGR) of 8.5%. This impending growth within the prediction phase could be primarily credited to the bolstering governmental backing, heightened accessibility to healthcare, surge in investments, and increased biopharmaceutical development, which will collectively fuel the market. The upcoming phase is expected to witness several trends like the emphasis on sustainability, integration of artificial intelligence and digitization, product innovation with a resilience focus, a surge in investments, and an increase in strategic alliances and collaborations among the participants in the market.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-developments-and-manufacturing-organization-cmo-global-market-report

Top Growth Drivers in the Pharmaceutical Contract Development And Manufacturing Organization (CMO) Industry: What's Accelerating the Market?
The expansion of the pharmaceutical contract development and manufacturing market is propelled by the global increase in medicine demand. The surge in disease prevalence and the quest for extended longevity further stimulate the requirement for medicines, compelling pharmaceutical firms to escalate production of existing drugs and heighten investment in research and development for new drugs creation. This, in turn, motivates pharmaceutical companies to synergize with contract manufacturing organizations (CMOs) to minimize operational expenses, hence, intensifying the need for the pharmaceutical contract development and manufacturing market. A statement from Alkermes PLC., a biopharmaceutical establishment, suggests that pharmaceutical contract manufacturing may serve as a tactical avenue for a wide array of companies, from larger ones to smaller specialty pharma entities, primarily because pharmaceutical firms are keen on cost reduction.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2825&type=smp

What Long-Term Trends Will Define the Future of the Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market?
Businesses in the pharmaceutical contract development and manufacturing market are strategically investing in mergers and acquisitions with other industry players. These moves reflect a trend among pharmaceutical contract development and manufacturing firms to broaden their global reach, satisfy customer requirements, enhance production abilities while preserving cost efficiencies, and acquire the latest technologies and new services. The frequent merger and acquisition activities lead to a consolidation of the contract service providers. Highlighting this trend, Pharma Nobis, a US-based firm specializing in contract manufacturing and private label services, completed the acquisition of Fagron's U.S. contract manufacturing division in July 2022. The specific financial details were not disclosed, but this move allows Pharma Nobis to extend its contract manufacturing and private label services to American retailers and consumer healthcare corporations. Notably, Fagron will retain a 20% stake in the company.

What Are the Main Segments in the Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market?
The pharmaceutical contract development and manufacturing organization (cmo) market covered in this report is segmented -

1) By Type: Contract Manufacturing Services, Contract Research Services
2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV
2) By End User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small And Medium-Sized Pharmaceutical Companies

Subsegments:
1) By Contract Manufacturing Services: Active Pharmaceutical Ingredient (API) Manufacturing, Formulation Development, Finished Dosage Form Manufacturing, Packaging Services, Supply Chain Management
2) By Contract Research Services: Preclinical Research Services, Clinical Trial Management, Regulatory Affairs Consulting, Biostatistics And Data Management, Analytical And Testing Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2825&type=smp

Which Top Companies are Driving Growth in the Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market?
Major companies operating in the pharmaceutical contract development and manufacturing organization (CMO) market include Lonza Group, Catalent Inc, WuXi AppTec Inc., Pfizer Inc, Recipharm AB, Almac Group, Aenova Group, Baxter International Inc, SGS Life Science Services SA, Jubilant Pharmova Ltd, Dishman Pharmaceuticals, Kemwell Pvt. Ltd., Nipro Corp., CMIC Group, Sawai Pharmaceutical Co., Ltd, IDT Australia Limited, Aurigene Pharmaceutical Services Limited, Vetter Pharma International GMBH, Consort Medical PLC, Siegfried Holding AG, Evonik Industries, NextPharma, Royal DSM N.V, HAUPT Pharma AG, Boehringer Ingelheim International GmbH, Famar, OTC-PharmNEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, AbbVie Inc, Merck & Co Inc, Amgen Inc, Gilead Sciences Inc, Regeneron Pharmaceuticals Inc, Vertex Pharmaceuticals Inc, Johnson & Johnson, Eurofarma Laboratórios S.A., Ache Laboratórios Farmacêuticos S.A., Blanver Farmoquímica e Farmacêutica S.A., Prati-Donaduzzi, União Química Farmacêutica Nacional S.A, Laboratorios Richmond S.A.C.I.F., Bago S.A., Elea Laboratories S.A.C.I. y F., Gador S.A., LIFEPharma, Neopharm, Gulf Pharmaceutical Industries JULPHA, NewBridge Pharmaceuticals Limited, Aspen Pharmacare Holdings Limited, Adcock Ingram Holdings Limited, Pharma-Q (Pty) Ltd, Vital Health Foods, EIPICO (Egyptian International Pharmaceutical Industries Company), Pharco Pharmaceuticals

Which Regions Will Dominate the Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Through 2029?
North America was the largest region in the global pharmaceutical contract development and manufacturing market in 2024. The Middle East is expected to be the fastest-growing region in the global pharmaceutical contract development and manufacturing market during the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cmo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2825

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.